<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020538</url>
  </required_header>
  <id_info>
    <org_study_id>382/13</org_study_id>
    <nct_id>NCT02020538</nct_id>
  </id_info>
  <brief_title>Limiting IV Chloride to Reduce AKI After Cardiac Surgery</brief_title>
  <acronym>LICRA</acronym>
  <official_title>Does Varying the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand College of Anaesthetists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This primary aim of this study is to test the impact of a strategy of perioperative
      chloride-restriction through intravenous (IV) fluid therapy on the incidence of acute kidney
      injury after cardiac surgery.

      A prospective, open-label, single-centre 4-period sequential study of varying strategies of
      perioperative IV fluid composition will test the hypothesis that a perioperative protocol for
      the administration of chloride-poor intravenous fluids compared to chloride-rich intravenous
      fluids will reduce the incidence of AKI after adult cardiothoracic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After an initial run-in period of approximately 1 month (using a chloride-rich fluid
      strategy), the first study period of 5 months will commence, also comprising a chloride-rich
      perioperative IV fluid therapy strategy (0.9% saline or 4% albumin). This will include
      intraoperative fluid and postoperative fluid for the duration of stay in the intensive care
      unit. This will then be followed by a 1-month transition period before a second period of 5
      months will commence where perioperative intravenous fluid therapy will consist of
      chloride-poor fluids (Lactated Ringer's solution or concentrated 20% albumin). A subsequent
      1-month transition period will then be followed by a third period of 5 months characterized
      by perioperative IV fluid therapy with an alternative combination of chloride-poor solutions
      (PlasmaLyte® 148 or concentrated 20% albumin). A final 1-month transition period will be
      followed by a fourth and final period of 5 months characterized by a return to perioperative
      IV fluid therapy with chloride-rich fluids (0.9% saline or 4% albumin). A final 1-month
      run-off period using a chloride-rich perioperative fluid strategy will follow prior to study
      completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2014</start_date>
  <completion_date type="Actual">February 12, 2016</completion_date>
  <primary_completion_date type="Actual">December 9, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Investigator-initiated, prospective, open-label, 4-period sequential study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak ∆ serum creatinine</measure>
    <time_frame>5 days postoperatively</time_frame>
    <description>Maximum change in serum creatinine from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AKI ≥stage2</measure>
    <time_frame>5 days postoperatively</time_frame>
    <description>AKI, ≥stage2, defined by creatinine-based KDIGO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual stages of AKI</measure>
    <time_frame>7 days</time_frame>
    <description>Individual stages of AKI, defined by creatinine-based KDIGO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of stay</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>ICU Length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Hospital Length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first extubation</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Time to first extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell transfusion requirement</measure>
    <time_frame>Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first</time_frame>
    <description>Volume of packed red blood cells transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fresh frozen plasma transfusion requirement</measure>
    <time_frame>Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first</time_frame>
    <description>Volume of fresh frozen plasma transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusion requirement</measure>
    <time_frame>Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first</time_frame>
    <description>Volume of platelets transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryoprecipitate transfusion requirement</measure>
    <time_frame>Intraoperative and postoperatively through completion of postoperative day 1 or ICU discharge, whichever occurred first</time_frame>
    <description>Volume of cryoprecipitate transfused</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time-weighted mean serum chloride concentration</measure>
    <time_frame>First 5 days and through ICU admission</time_frame>
    <description>A time-weighted calculation of mean serum chloride concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypernatremia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of hypernatremia (SNa+ &gt;150 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hyponatremia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of hyponatremia (SNa+ &lt;130 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hyperchloremia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of hyperchloremia (SCl- &gt;110 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypochloremia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of hypochloremia (SCl- &lt;96 mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of acidemia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of acidemia (pH &lt;7.3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of alkalemia</measure>
    <time_frame>On discharge from hospital (7-30 days)</time_frame>
    <description>Incidence of alkalemia (pH &gt;7.5)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1298</enrollment>
  <condition>Patients Undergoing Cardiothoracic Surgery</condition>
  <arm_group>
    <arm_group_label>Chloride-rich IV fluid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloride-poor IV fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-chloride perioperative intravenous fluid strategy</intervention_name>
    <description>The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.</description>
    <arm_group_label>Chloride-poor IV fluid</arm_group_label>
    <other_name>Chloride-poor IV fluid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High-chloride perioperative intravenous fluid strategy</intervention_name>
    <arm_group_label>Chloride-rich IV fluid</arm_group_label>
    <other_name>Chloride-rich IV fluid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All adult patients undergoing surgery by Division of cardiothoracic surgery

        Exclusion Criteria:

        Nil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R McIlroy, MBBS, MClinEpi, FANZCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred Hospital and Monash University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thoracic surgery</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>hyperchloremia</keyword>
  <keyword>intravenous fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

